PROLIFERATIVE RESPONSE OF B-CHRONIC LYMPHOCYTIC-LEUKEMIA LYMPHOCYTES STIMULATED WITH IL2 AND SOLUBLE CD23

被引:8
作者
BRIZARD, A
MOREL, F
LECRON, JC
DREYFUS, B
BRIZARD, F
BARRA, A
PREUDHOMME, JL
机构
[1] Département d'Hématologie et Oncologic Médicale
[2] Laboratoire d'Immunologie et Interactions Moléculaires (CNRS URA 1172), CHU La Mitétrie, 86021 Poitiers Cedex
关键词
B-CLL; SCD23; IL-2; PROLIFERATION; LYMPHOKINES;
D O I
10.3109/10428199409049683
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The in vitro proliferative response of purified B-chronic lymphocytic leukemia (B-CLL) lymphocytes cultured in the presence of soluble CD23 (sCD23) with or without IL2 was compared to the responses induced by phorbol 12-myristate 13-acetate (PMA), Staphylococcus aureus strain Cowan I (SAC), IL1, IL2, IL4, IL6 and the combination of IL2 and interferon (IFN) cu or IFN gamma. As expected, B-CLL lymphocytes proliferated with PMA, SAC and IL2 with a clear enhancement of the IL2-induced response by IFN alpha or IFN gamma. They failed to proliferate in response to sCD23, IL1, IL4 or IL6 alone nor to the combinations of sCD23 and any of the 3 latter cytokines. However, sCD23 significantly increased the proliferation of B-CLL cells induced by IL2, suggesting a protective effect of sCD23 on apoptosis. Serum levels of sCD23 and CD23 membrane expression were high in every patient which is compatible with the hypothesis of an autocrine or paracrine activation loop. Detectable CD23 expression was lost in all cultures except for that stimulated by PMA. Only supernatants of PMA-stimulated cultures contained high sCD23 levels.
引用
收藏
页码:311 / 318
页数:8
相关论文
共 37 条
  • [21] Hahn T., Shulman L., Karov Y., Vorst E., Berrebi A., Involvement of interleukin-6 in the autocrine stimulation of chronic lymphocytic leukemia B cells by tumor necrosis factor, Leukemia & Lymphoma, Suppl, pp. 65-69, (1991)
  • [22] Fournier S., Tran I.D., Suter U., Biron G., Delespesse G., Sarfati M., The in vivo expression of type B CD23 mRNA in B-chronic lymphocytic leukemic cells is associated with an abnormally low CD23 upregulation by IL-4: comparison with their normal cellular counterparts, Leukemia Res., 15, pp. 609-618, (1991)
  • [23] Fournier S., Delespesse G., Rubio M., Biron G., Sarfati M., CD23 antigen regulation and signaling in chronic lymphocytic leukemia, J. Clin. Invest., 89, pp. 1312-1321, (1992)
  • [24] Knuutila S., Elonen E., Teerenhovi L., Rossi L., Leskinen R., Bloomfield C.D., De La Chapelle A., Trisomy 12 in B cells of patients with B-cell chronic lymphocytic leukemia, N. Engl. J. Med., 314, pp. 865-869, (1986)
  • [25] Autio K., Elonen E., Teerenhovi L., Knuutila S., Cytogenetic and immunologic characterization of mitotic cells in chronic lymphocytic leukaemia, Eur. J. Haematol., 39, pp. 289-298, (1987)
  • [26] Brizard A., Brizard F., Dreyfus B., Morel F., Lecron J.C., Tanzer J., Preu d'Homme J.L., Chromosomal analysis of purified B-chronic lymphocytic leukemia lymphocyte cultures. Comparison with whole blood cultures and in situ hybridization, Leukemia & Lymphoma, (1993)
  • [27] Binet J.L., Auquier A., Dighiero G., Chatang C., Piguet H., Goasguen J., Vaugier G., Potron G., Colona P., Oberling F., Thomas M., Tchernia G., Jacquillat A.T.C., Boivin P., Lesty C., Duault M.T., Monconduit M., Belabbes S., Gremy F., A new prognostic classification of chronic lymphocytic leukemia derived from a multivaried survival analysis, Cancer, 48, pp. 198-206, (1981)
  • [28] Rai K.R., Sawitsky A., Cronkite E.P., Channa A.D., Levy R.N., Pasternack B.S., Clinical staging of chronic lymphocytic leukemia, Blood, 46, pp. 219-234, (1975)
  • [29] Pellegrino M.A., Ferrone S., Dierich M.P., Enhancement of sheep red blood cell human lymphocyte rosette formation by the sulfhydril compound 2-amino-ethyl-isothio-uronium bromide, Clin. Immunol. Immunopathol., 3, pp. 324-329, (1975)
  • [30] Pezzella F., Tse A.G.D., Cordell J.L., Pulford K.A.F., Gatter K.C., Mason D.Y., Expression of the bcl-2 oncogene protein is not specific for the 14